Nordic Capital

Founded in 1989, Nordic Capital is a global private equity firm that has grown to manage approximately $50 billion in capital. The firm is recognized as one of the largest private equity firms globally, consistently ranking in the PEI 300. It operates with a sector-specialist approach, maintaining a strong presence across Northern Europe and North America through a network of ten international offices.

The firm primarily targets buyouts of large-cap and upper mid-market companies, with a specialized focus on four core industries: Technology & Payments, Healthcare, Financial Services, and Services & Industrial Technology. Notable for its fundraising capabilities, Nordic Capital successfully closed its 11th large-cap fund at 9 billion Euros in 2022 and its second mid-market evolution fund at 2 billion Euros in 2024.

Nordic Capital has a history of high-value exits and significant deal activity. Historical highlights include the $14 billion sale of Nycomed to Takeda in 2011, which was one of the most profitable private equity deals ever recorded. More recently, the firm has executed multi-billion dollar deals such as the $9.4 billion sale of Clario to Thermo Fisher Scientific and the $7 billion take-private of Hargreaves Lansdown.